VYGR
Voyager Therapeutics, Inc.4.4200
+0.0600+1.38%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
245.75MP/E (TTM)
-Basic EPS (TTM)
-2.17Dividend Yield
0%Recent Filings
8-K
Q4 results, strong cash runway
Voyager Therapeutics reported Q4 and full-year 2025 results on March 9, 2026, with collaboration revenue up to $15.3M quarterly yet down to $40.4M annually, R&D steady at $134.7M, and net loss widening to $119.7M. Cash stands at $202M, funding operations into 2028. Pipeline heats up: VY1706 enters clinic H2 2026; tau data looms. Cash fuels the push.
10-K
FY2025 10-K filed
Voyager Therapeutics filed its 10-K for FY2025 ended December 31, 2025, but financial statements and quarterly results are not disclosed in the provided filing. In June 2025, Voyager expanded its research collaboration with Transition Bio, replacing a prior agreement to advance small molecule TDP-43 modulators for ALS and FTD using TBI's condensate platform. The deal includes research milestones, an option for Voyager to exclusively license resulting compounds, and potential development/sales milestones plus royalties—not yet triggered. No revenue, EPS, cash flow, debt, or capex details provided. Clinical trial delays could stall quarterly momentum.
8-K
CMO resigns; CEO assumes duties
8-K
Tau programs gear up for 2026
Voyager Therapeutics posted its January 2026 corporate investor presentation and stockholder letter under Item 7.01, spotlighting 2026 as transformative for tau programs: VY7523 anti-tau antibody tau PET data and VY1706 gene therapy first-in-human dosing both eyed for H2. Neurocrine plans NBIB-'223 clinic entry for Friedreich's ataxia in 2026. Cash runway extends into 2028. 2026 packs two tau shots.
8-K
Q3 loss widens on tau push
Voyager Therapeutics reported Q3 2025 results, with collaboration revenue dropping to $13.4 million from $24.6 million year-over-year amid higher R&D spend of $35.9 million on tau programs VY7523 and VY1706; net loss widened to $27.9 million. Cash stands at $229 million, funding operations into 2028. Pipeline sharpens on NeuroShuttle platform and Transition Bio ALS/FTD deal. Momentum builds around tau.
IPO
Employees
Sector
Industry
ALEC
Alector, Inc.
1.39-0.03
ALZN
Alzamend Neuro, Inc.
2.16+0.05
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
COYA
Coya Therapeutics, Inc.
5.83-0.08
LXEO
Lexeo Therapeutics, Inc.
9.73-0.03
NGNE
Neurogene Inc.
19.53-0.73
PASG
Passage Bio, Inc.
9.45-0.60
RGNX
REGENXBIO Inc.
14.11+0.28
VKTX
Viking Therapeutics, Inc.
35.72-0.43
VTGN
VistaGen Therapeutics, Inc.
4.36-0.03